Last updated: February 19, 2026
Fenofibrate is a widely used lipid-lowering agent, primarily prescribed for hyperlipidemia. It is available from numerous manufacturers globally, with key suppliers holding various regulatory approvals and manufacturing capacities.
Leading Manufacturers of Fenofibrate
| Company Name |
Country |
Key Markets |
Manufacturing Capacity |
Regulatory Approvals |
| Mylan (Now part of Viatris) |
United States / India |
U.S., E.U., Asia |
Large-scale production |
FDA, EMA, WHO GMP |
| Teva Pharmaceutical Industries |
Israel |
Global |
Extensive manufacturing |
FDA, EMA, Health Canada, others |
| Sandoz (Novartis) |
Switzerland |
North America, Europe, Asia |
High-volume facility |
FDA, EMA, MHRA |
| Sun Pharmaceutical |
India |
India, U.S., Asia, Africa |
Major capacities |
US FDA, EU regulators |
| Lupin Limited |
India |
India, U.S., African markets |
Large-scale capacity |
US FDA, EMA |
| Aurobindo Pharma |
India |
Global |
Significant capacity |
US FDA, EMA |
| Apotex |
Canada |
North America |
Multiple facilities |
FDA, Health Canada |
| Ranbaxy (Now part of Sun Pharma) |
India |
Global |
Key manufacturing hubs |
FDA, EMA, other regional agencies |
Regulatory Landscape
- FDA (U.S. Food and Drug Administration): Approved manufacturers supply fenofibrate in the U.S. market. FDA approval requires Good Manufacturing Practice (GMP) compliance.
- EMA (European Medicines Agency): Approvals in Europe are held by companies with EMA marketing authorizations; many suppliers also hold European GMP certifications.
- WHO GMP: A key standard for global distribution, especially for manufacturers aiming to export to developing markets.
Supply Chain Considerations
- Bulk Production: Major suppliers produce fenofibrate APIs at capacities ranging from hundreds of kilograms to several tons annually.
- API Quality Standards: Suppliers adhere to specifications including assay purity (>99%), residual solvents under limits, and compliance with pharmacopoeias.
- Generic Competition: Market features numerous generic suppliers, leading to price competition and supply stability.
Market Share and Pricing
- The dominant suppliers in the global API market include Mylan, Teva, Sun Pharma, and Lupin.
- Prices vary depending on source, purity, and regulatory approvals but generally range from $50 to $200 per kilogram for high-quality API.
Distribution Channels
- APIs are sold directly to pharmaceutical companies for formulation manufacturing.
- Distribution involves authorized distributors and regional agents, especially in emerging markets.
Key Trends
- Increasing production capacity among Indian manufacturers.
- Expansion into emerging markets with lower regulatory barriers.
- Investment in quality certifications to access developed markets.
- Future growth driven by biosimilar and generic blood lipid-lowering therapies.
Summary
Supply of fenofibrate originates from multiple global manufacturers, predominantly based in India, Israel, Switzerland, and the U.S. Each supplies APIs meeting international regulatory standards, with capacity growth driven by demand for lipid-lowering agents worldwide. Storage, batch consistency, and regulatory compliance are critical for sourcing reliable fenofibrate supplies.
Key Takeaways
- The primary suppliers include Mylan, Teva, Sun Pharma, Lupin, and Aurobindo.
- Regulatory approvals from FDA and EMA are essential for supply in developed markets.
- Indian-based manufacturers dominate API production, offering competitive pricing.
- Supply chains rely on GMP-certified manufacturing facilities and distribution networks.
- Market growth continues due to increasing prevalence of hyperlipidemia globally.
FAQs
1. Who are the top fenofibrate API producers globally?
Major players include Mylan (Viatris), Teva, Sun Pharma, Lupin, and Aurobindo, primarily based in India, Israel, and Switzerland.
2. What regulatory approvals are necessary for fenofibrate supply?
Manufacturers typically hold FDA, EMA, or WHO GMP certifications to export and sell in various markets.
3. Which region has the highest fenofibrate manufacturing capacity?
India has the highest capacity, with multiple companies expanding API production to meet global demand.
4. How does API quality impact marketability?
Higher purity standards, compliance with pharmacopoeias, and GMP certification influence regulatory approval and market acceptance.
5. Are there significant price differences among suppliers?
Yes. Indian generic manufacturers tend to offer lower prices, while more established Western companies may command premium pricing due to stricter regulatory compliance and brand reputation.
Sources
[1] U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations.
[2] European Medicines Agency. (2022). List of authorized medicines.
[3] IQVIA. (2023). Global API market analysis.
[4] Pharmapark. (2023). API manufacturing capacities and trends.
[5] GlobalData. (2023). Pharmaceutical API supplier profiles.
